Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension safety study of Epoprostenol in pulmonary arterial hypertension
2010-018320-10Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of epoprostenol in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Safety and tolerability. Started Apr 2010; status: completed.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2010-018320-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018320-10.